Source link : https://www.newshealth.biz/health-news/rilzabrutinib-shines-in-phase-3-trial-of-tough-to-treat-itp/
Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA 3 trial, treatment with rilzabrutinib (Sanofi) led to rapid and durable platelet responses, reduced bleeding and need for rescue therapy, and improved health-related quality of life in patients with […]
Author : News Health
Publish date : 2024-12-08 15:33:03
Copyright for syndicated content belongs to the linked Source.